ལྗིད་ཚད་
x
དྲ་ཚིགས་འདི་གིས་ ཁག་ཆེ་བའི་ཀུ་ཀི་ཚུ་ལག་ལེན་འཐབ་ཨིན། ཁྱོད་ཀྱི་གནང་བ་དང་གཅིག་ཁར་ ང་བཅས་ཀྱིས་ གུ་གཱལ་ཨེ་ན་ལི་ཊིག་ཀུ་ཀི་ཚུ་ རྩིས་དཔྱད་ཀྱི་དོན་ལུ་ བཙུགསཔ་ཨིན།

Slzii.com

Slzii.com, accessible from slzii.com

What Are Cookies

As is common practice with almost all professional websites this site uses cookies, which are tiny files that are downloaded to your computer, to improve your experience. This page describes what information they gather, how we use it and why we sometimes need to store these cookies. We will also share how you can prevent these cookies from being stored however this may downgrade or 'break' certain elements of the sites functionality.

How We Use Cookies

We use cookies for a variety of reasons detailed below. Unfortunately in most cases there are no industry standard options for disabling cookies without completely disabling the functionality and features they add to this site. It is recommended that you leave on all cookies if you are not sure whether you need them or not in case they are used to provide a service that you use.

Disabling Cookies

You can prevent the setting of cookies by adjusting the settings on your browser (see your browser Help for how to do this). Be aware that disabling cookies will affect the functionality of this and many other websites that you visit. Disabling cookies will usually result in also disabling certain functionality and features of the this site. Therefore it is recommended that you do not disable cookies. This Cookies Policy was created with the help of the Cookies Policy Generator.

The Cookies We Set

  • Account related cookies

    If you create an account with us then we will use cookies for the management of the signup process and general administration. These cookies will usually be deleted when you log out however in some cases they may remain afterwards to remember your site preferences when logged out.

  • Login related cookies

    We use cookies when you are logged in so that we can remember this fact. This prevents you from having to log in every single time you visit a new page. These cookies are typically removed or cleared when you log out to ensure that you can only access restricted features and areas when logged in.

  • Site preferences cookies

    In order to provide you with a great experience on this site we provide the functionality to set your preferences for how this site runs when you use it. In order to remember your preferences we need to set cookies so that this information can be called whenever you interact with a page is affected by your preferences.

Third Party Cookies

In some special cases we also use cookies provided by trusted third parties. The following section details which third party cookies you might encounter through this site.

  • This site uses Google Analytics which is one of the most widespread and trusted analytics solution on the web for helping us to understand how you use the site and ways that we can improve your experience. These cookies may track things such as how long you spend on the site and the pages that you visit so we can continue to produce engaging content.

    For more information on Google Analytics cookies, see the official Google Analytics page.

  • Third party analytics are used to track and measure usage of this site so that we can continue to produce engaging content. These cookies may track things such as how long you spend on the site or pages you visit which helps us to understand how we can improve the site for you.

  • From time to time we test new features and make subtle changes to the way that the site is delivered. When we are still testing new features these cookies may be used to ensure that you receive a consistent experience whilst on the site whilst ensuring we understand which optimisations our users appreciate the most.

  • We also use social media buttons and/or plugins on this site that allow you to connect with your social network in various ways. For these to work the following social media sites including; {List the social networks whose features you have integrated with your site?:12}, will set cookies through our site which may be used to enhance your profile on their site or contribute to the data they hold for various purposes outlined in their respective privacy policies.

More Information

Hopefully that has clarified things for you and as was previously mentioned if there is something that you aren't sure whether you need or not it's usually safer to leave cookies enabled in case it does interact with one of the features you use on our site.

For more general information on cookies, please read the Cookies Policy article.

However if you are still looking for more information then you can contact us through one of our preferred contact methods:

  • By visiting this link: https://www.slzii.com/contact

འཚོལ་ཞིབ་འབད་ (གསར་ཤོག་)

Insilico and TaiGen Achieve Milestone in Collaboration: Out-Licensed CKD Anemia Candidate ISM4808 Completes first human enrollment and dosing in Phase I clinical trial
CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Insilico Medicine (Insilico Medicine, HKEX: 03696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), announced that ISM4808, an AI-driven PHD inhibitor for chronic kidney disease (CKD)-related anemia previously out-licensed to TaiGen Biotechnology (TaiGen*-KY, 4157), has achieved its first milestone. Recently, TaiGen has successfully completed the enrollment and dosing of the first subject in the Phase I clinical trial. The prevalence of CKD is steadily rising in the Greater China region. Anemia is one of the most common complications of CKD, affecting more than one in seven patients. ISM4808 is a potential best-in-class oral HIF-PHD inhibitor discovered with the support of Insilico Medicine's generative chemistry platform, Chemistry42. Compared to traditional Erythropoiesis-Stimulating Agents (ESAs), ISM4808 stimulates the production of endogenous erythropoietin (EPO) and improves iron utilization. Its advantages, offering multiple advantages including improved iron use efficiency, avoidance of intravenous injections, and a favorable safety profile, with the potential to overcome limitations of existing treatment. In December 2025, Insilico and TaiGen entered into a licensing agreement for the program. Under the agreement, TaiGen obtained exclusive rights to develop, commercialize, and sublicense ISM4808 in Greater China (including mainland China, Hong Kong, Macau, and Taiwan). Insilico Medicine is eligible to receive an upfront payment, development and sales-based milestone payments, as well as tiered royalties on net sales, with the total deal value reaching tens of millions of US dollars. Since entering the collaboration, TaiGen has efficiently initiated preparations for the Phase I clinical trial of this program. The Phase I clinical study is a randomized, double-blind, placebo-controlled trial comprising both single-ascending-dose (SAD) and multiple-ascending-dose (MAD) cohorts, designed to evaluate the safety, tolerability, and pharmacokinetic profile of ISM4808 in healthy adults. Kuo-Lung Huang, Chairman of TaiGen Biotechnology, said, "ISM4808 is an important milestone in TaiGen's drug development strategy. Within 3 months of in-licensing the program, our team completed the challenging process from regulatory preparation to first-subject enrollment and dosing, demonstrating TaiGen's clinical development expertise. There remains significant unmet medical need in the CKD anemia market. We look forward to providing patients with a safer and more convenient oral treatment option through this novel mechanism, and we will continue to accelerate clinical progress to advance into the next stage of development as soon as possible." Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine, said, "We are deeply impressed by our partner TaiGen, who achieved clinical enrollment in less than three months after in-licensing the program. This highly efficient translational model—'AI-enabled early discovery + professional clinical development'—greatly shortens the distance from concept to the clinic. We look forward to ISM4808 delivering strong outcomes in clinical trials and bringing a clinically differentiated new oral treatment option to the broader CKD anemia patient community. ISM4808 was initially discovered as a candidate drug targeting the PHD mechanism with the support of Chemistry42. Garutadustat, another drug candidate targeting the PHD discovered and optimized by Chemistry42, is being independently advanced by Insilico for the treatment of inflammatory bowel disease. The first patient dosing for its Phase II clinical trial was completed in January 2026." About Insilico Medicine Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend health longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, HKEX:3696. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com.
2026-03-06 10:53:00

0.036571979522705


གསར་ཤོག་
གསར་ཤོག་

གནས་ཚུལ་གསར་བཏོན་དང་ གནས་ཚུལ་གསར་བཏོན་
CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Insilico Medicine (Insilico Medicine, HKEX: 03696), a clinical-stage biotechnology company p...
གསར་ཤོག་